3,5-T2—A Janus-Faced Thyroid Hormone Metabolite Exerts Both Canonical T3-Mimetic Endocrine and Intracrine Hepatic Action
Open Access
- 8 January 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 787
Abstract
Over the last decades, thyroid hormone metabolites (THMs) received marked attention as it has been demonstrated that they are bioactive compounds. Their concentrations were determined by immunoassay or mass-spectrometry methods. Among those metabolites, 3,5-diiodothyronine (3,5-T2), occurs at low nanomolar concentrations in human serum, but might reach tissue concentrations similar to those of T4 and T3, at least based on data from rodent models. However, the immunoassay-based measurements in human sera revealed remarkable variations depending on antibodies used in the assays and thus need to be interpreted with caution. In clinical experimental approaches in euthyroid volunteers and hypothyroid patients using the immunoassay as the analytical tool no evidence of formation of 3,5-T2 from its putative precursors T4 or T3 was found, nor was any support found for the assumption that 3,5-T2 might represent a direct precursor for serum 3-T1-AM generated by combined deiodination and decarboxylation from 3,5-T2, as previously documented for mouse intestinal mucosa. We hypothesized that lowered endogenous production of 3,5-T2 in patients requiring T4 replacement therapy after thyroidectomy or for treatment of autoimmune thyroid disease, compared to production of 3,5-T2 in individuals with intact thyroid glands might contribute to the discontent seen in a subset of patients with this therapeutic regimen. So far, our observations do not support this assumption. However, the unexpected association between high serum 3,5-T2 and elevated urinary concentrations of metabolites related to coffee consumption requires further studies for an explanation. Elevated 3,5-T2 serum concentrations were found in several situations including impaired renal function, chronic dialysis, sepsis, non-survival in the ICU as well as post-operative atrial fibrillation (POAF) in studies using a monoclonal antibody-based chemoluminescence immunoassay. Pilot analysis of human sera using LC-linear-ion-trap-mass-spectrometry yielded 3,5-T2 concentrations below the limit of quantification in the majority of cases, thus the divergent results of both methods need to be reconciliated by further studies. Although positive anti-steatotic effects have been observed in rodent models, use of 3,5-T2 as a muscle anabolic, slimming or fitness drug, easily obtained without medical prescription, must be advised against, considering its potency in suppressing the HPT axis and causing adverse cardiac side effects. 3,5-T2 escapes regular detection by commercially available clinical routine assays used for thyroid function tests, which may be seriously disrupted in individuals self-administering 3,5-T2 obtained over-the counter or from other sources.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 100 references indexed in Scilit:
- Coordination of hypothalamic and pituitary T3 production regulates TSH expressionJournal of Clinical Investigation, 2013
- Metabolic Effects of Liothyronine Therapy in Hypothyroidism: A Randomized, Double-Blind, Crossover Trial of LiothyronineVersusLevothyroxineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-L-Thyronine in RatsDiabetes, 2011
- Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3′,5′-triiodothyronineDevelopmental Brain Research, 2005
- Development and Evaluation of a Reference Measurement Procedure for the Determination of Total 3,3‘,5-Triiodothyronine in Human Serum Using Isotope-Dilution Liquid Chromatography−Tandem Mass SpectrometryAnalytical Chemistry, 2004
- Triac regulation of transcription is T3 receptor isoform- and response element-specificMolecular and Cellular Endocrinology, 2000
- Rapid stimulation in vitro of rat liver cytochrome oxidase activity by 3,5-diiodo-l-thyronine and by 3,3′-diiodo-l-thyronineMolecular and Cellular Endocrinology, 1994
- A RADIOIMMUNOASSAY FOR 3,5-DIIODOTHYRONINEClinical Endocrinology, 1978
- Conversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjectsJournal of Clinical Investigation, 1970
- THE IDENTIFICATION OF 3:5:3'-L-TRIIODOTHYRONINE IN HUMAN PLASMAThe Lancet, 1952